2578
Views & Citations1578
Likes & Shares
Introduction:
Cancer is still a challenge when it comes to its successful treatment and
rehabilitation of patient. With chemotherapy, radiotherapy, surgery and latest
cancer immunotherapy, we are still far away from curing the disease.
High dose ascorbic acid in treatment of Cancers has its
roots in work of Prof Linus Pauling, way back in 1972.
This study included all kinds of Cancers, Ca Breast, Ca
Lung, Adenocarcinoma Colon, Chronic Myeloid Leukemia, etc. Further, this study
is to expand the literature on role of high dose ascorbic acid on cancer
progression and metastasis.
Methods: Thirty
two patients were treated with high dose ascorbic acid therapy (1.5 g/kg body
weight) with modifications in patients with renal insufficiency. No inclusion
or exclusion criteria were applied in above study. Patients were divided in 5
categories: (a) Recently diagnosed who received only high dose ascorbic acid
therapy; (b) Cancer patients who received complete conventional cancer therapy
but with Recurrence; (c) Cancer patients who dropped out of conventional cancer
therapy because of intolerable side effects of chemotherapy or radiotherapy;
(d) Cancer patients on palliative therapy, end stage metastatic disease; (e)
Drop out cases of high dose ascorbic acid therapy. Target plasma ascorbic acid
concentration was >350 mg/ dl (Normal is 0.70-1.4 mg/ dl). Patients were
checked for G6PDase status and all patients in study were not deficient for it.
Four patients were drop outs of high dose ascorbic acid
therapy and were not included in the study. 15 of 28 patients were females and
had Ca Breast, Ca Ovary, Ca Cervix, Ca Colon, Neuroendocrine metastasis stage
II/III. 13 male patients suffered from testicular carcinoma, prostatic Ca,
Non-Hodgkin’s lymphoma, Esophageal Ca, Bladder Ca and Liver Ca, Chronic Myeloid
Leukemia.
Patients were given high dose ascorbic acid therapy for
first 5-7 days, followed by 10gms of oral ascorbic acid for 3 weeks and such
cycles for total 6 months.
Patients were followed at 1 year, 2 years and 5 years.
Results: There
are 4 survivors till date, 2 males (Ca Prostate, Cat b, Testicular Ca Stage II,
Cat b), 2 Females (Ca Breast Stage III, Cat b, NEM stage IV, Cat a) and they
underwent complete high dose ascorbic acid therapy.
Conclusion:
Cancer patients, who have undergone conventional cancer therapy, benefit from
high dose ascorbic acid therapy as a supportive care. They benefit in terms of
alleviation of cancer pain, generalized weakness, slowing down of progression
of metastasis and improvement in cancer induced Anemia. High dose ascorbic acid
therapy does not cure cancer. High dose ascorbic acid has a definitive place as
supportive therapy in whole treatment plan of a cancer patient.
QUICK LINKS
- SUBMIT MANUSCRIPT
- RECOMMEND THE JOURNAL
-
SUBSCRIBE FOR ALERTS
RELATED JOURNALS
- International Journal of Surgery and Invasive Procedures (ISSN:2640-0820)
- Stem Cell Research and Therapeutics (ISSN:2474-4646)
- Journal of Cardiology and Diagnostics Research (ISSN:2639-4634)
- International Journal of Clinical Case Studies and Reports (ISSN:2641-5771)
- International Journal of AIDS (ISSN: 2644-3023)
- Journal of Renal Transplantation Science (ISSN:2640-0847)
- Ophthalmology Clinics and Research (ISSN:2638-115X)